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Abstract: The clinical studies regarding the effect of L-arginine in human anthropometry have not been fully consistent, therefore, we carried
out a systematic review and meta-analysis of randomized clinical trials in order to precisely evaluate and quantify the efficacy of L-arginine on
weight, waist circumference, and BMI. We searched online databases including PubMed, SCOPUS, and Google Scholar for relevant articles up
to September 2017. Eligible articles were reviewed by two independent investigators. Mean differences of the outcomes were used for
calculation of weighted mean difference (WMD) derived from the random-effects model. Statistical heterogeneity between studies was
examined using Cochran’s Q-test and I2 index. Funnel plot and Egger’s tests were performed to assess the publication bias. In our initial
search, we found 1598 publications, of which 8 RCTs (9 treatment arms) were included. The results of the meta-analysis displayed a significant
reduction in WC following L-arginine supplementation (WMD: 2.97 cm; 95% CI: 4.75 to 1.18, P = 0.001). However, L-arginine intervention
had not elicited a significant effect on BMI (WMD: 0.51 kg/m2; 95% CI: 1.11 to .08, P = 0.09) and body weight (WMD: 0.57 kg; 95% CI:
1.77 to 0.61, P = 0.34). Subgroup analyses displayed that longer-term interventions (8 weeks) had a positive effect on body weight and
using < 8 g/day L-arginine with longer duration (8 weeks) could significantly decrease BMI. In conclusion, this meta-analysis result suggested
L-arginine supplementation could reduce waist circumference without any significant effect on body weight and body mass index.
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Introduction
Obesity is a global epidemic which impacts a wide range of
ages and ethnicities [1]. According to the World Health
Organization (WHO), approximately 600 million adults
all over the world were classified as obese in 2016 [2]. Obe-
sity is a major contributing risk factor for various chronic
diseases such as cardiovascular disease (CVD), Type 2Dia-
betes Mellitus (T2DM), joint and muscular diseases, and
psychological disorders [2–4].
The serum concentrations of Nitric Oxide (NO) in over-
weight subjects is higher than individuals with normal
weight. Thismay be partially due to the increased inducible
NO Synthase (iNOS) expression in obesity [5]. NO
decreases oxidative stress and improves insulin sensitivity
which contributes to weight balance [6]. The oxidative
stress in relation to NO is due to unpaired electron and free
uncharged radical of NO [7]. On the other hand, the white
adipose tissue is a potential source of NO production
through Endothelial and inducible NO synthase (eNOS


































































and iNOS). NO through insulin-stimulated uptake of glu-
cose could be involve in adipose tissue metabolism [8].
However, iNOS tends to increase the NO concentration to
detrimental levels in overweight subjects [9–11].
In recent years, due to the failure of conventional
approaches (diet and exercise) in weight reduction, use of
alternativemedicines suchasweight loss supplementshave
been proposed [12, 13]. L-arginine is a semi-essential amino
acidwhichparticipates inNOproduction thoroughNOsyn-
thase (NOS), free radical scavenging and nitrogen balance
improvement [5, 9, 10]. Prior studies have demonstrated
L-arginine supplementation can improve endothelial func-
tion, insulin secretion and sensitivity, and inflammation; all
of which have been linked to obesity-related complications
like T2DM and CVDs [14–17]. NO synthase pathway has
been proposed as a possible mechanism which improve
peripheral and hepatic insulin sensitivity following arginine
administration [18]. Therefore, the elevated concentration
of NO induced by L-arginine supplementation may also
improveweight control amongoverweight patients. Several
studies evaluated the potential effect of L-arginine supple-
mentation in obese patients. Previous publications indi-
cated that arginine can reduce waist circumference (WC)
[19, 20], BMI and body weight [20–22]. In contrast, some
other studies could not find a significant effect of arginine
supplementation on anthropometric measurements,
includingBMI,body fatmassand leanbodymass [6,23,24].
Given these evidences, clinical trials concerning the
effect of L-arginine on human anthropometric indices have
not been fully consistent. Therefore, we aimed to perform a
comprehensive systematic review and meta-analysis of
available randomized controlled trials (RCTs) to assess
the efficacy of L-arginine on body weight, BMI, and waist
circumference in adults.
Methods
The current meta-analysis was performed and reported
based on the PRISMA guideline [25].
Search strategy
We searched online databases including PubMed, SCO-
PUS, andGoogle Scholar for relevant articles up to Septem-
ber2017. Keywords thatweused inour searchstrategywere
selected from MeSH and non-MeSH terms including:
(“Arginine OR “L-arginine” OR “L-Arg” OR “Arg”) AND
(“Obesity” OR “Weight Loss” OR “weight reduce” OR
“weight decrease”OR “weight change”OR “BodyWeight”
OR “Obesity, Abdominal” OR “Body Mass Index” OR
“Waist Circumference” OR “obes*” OR “central obesity “
OR “overweight” [tiab] OR “adipose tissue”OR “fatmass”
OR “adiposity”). We did not limit our search to time and
language of publication. Moreover, we reviewed the
reference lists of all review articles to avoid missing any
publication. Unpublished studies were not included in this
meta-analysis.
Inclusion criteria
Any clinical trial that examined the effect of L-arginine sup-
plementation on body weight and/or BMI and/or WC in
adults were included in this systematic review and meta-
analysis. Amongst articles with the same data set, only the
most complete one was included [19].
Exclusion criteria
Studieswere excluded if theywere: (1) not randomized clin-
ical trials in design (2) carried out in children, pregnant
women and animals (3) trials with less than 2-weeks inter-
vention duration (4) not written in English (5) examined
the effect of L-arginine in combination with other interven-
tions (6) lacked a suitable control group (7) not reported
adequate information on baseline or after the intervention
for outcomes of interest.
Data extraction
Two investigators reviewed the eligible articles indepen-
dently (S.M.M and H.K.V), and the relevant data including
first author’s name, year of publication, type of study popu-
lation, sample size, participants’ gender, L-arginine dosage,
Duration of intervention,mean (SD) of participants’weight
before and after intervention,mean (SD) of BMI before and
after intervention, mean (SD) ofWC before and after inter-
vention were extracted. All reported Standard Errors (SEs),
interquartile ranges, and 95% confidence intervals were
converted to SDs. If a study was performed on two separate
groups with different dosage of supplementation, we con-
sidered this studyas twodisparate studies. Inorder toobtain
missing data in studies without a complete dataset, we con-
tacted the corresponding author.
Statistical analysis
Changes in bodyweight, BMI, andWCduring the interven-
tion, for the intervention and placebo groups, were used to
calculate the weightedmean difference (WMD) by the ran-
dom-effectsmodel. In the studies which not reported SD of
the changes, it was calculated by the following formula: SD2
= ((SDbesline)
2+ (SDfinal)
2 (2R SDbesline SDfinal)). A cor-
relation coefficient of 0.8 was considered as R-value in the
aforementioned formula [26]. Statistical heterogeneity
between studies was examined using the Cochran’s Q-test
and I2 static. To find possible sources of heterogeneity, we
carried out subgroup analyses based on the L-arginine
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tion (˂8weeks and 8weeks).We also performed sensitiv-
ity analysis to explore the extent to which inferences might
depend on an individual study or group of studies [27].
Visual inspection of funnel plots aswell as Egger’s test were
used to assess publication bias. All statistical analyses were
conducted using the Stata software (version 14, StataCorp
LP,CollegeStation,Texas).Pvalues less than0.05wascon-
sidered as statistically significant.
Results
General characteristics of included
studies
Our initial search resulted in 1598 probably related articles.
After removing 303 duplicate articles, 1295 records
remained and were reviewed based on title and abstract.
Out of these articles, 51 relevant records were nominated
for a careful full-text assessment. At this stage, 43 studies
were excluded due to: were done on children or patients
with chronic illnesses (n = 4), animal studies (n = 9), were
not available as English full-text (n =4), trials with the same
population (n = 6), examined the effect of other interven-
tions, along with L-arginine supplementation (n = 6), did
not have a suitable control group (n = 7), and studies which
reported incompletedata (n= 7). Finally,8 randomizedcon-
trolled trials met our criteria and were included in this sys-
tematic review and meta-analysis. The flow-diagram of
study selection is shown in Figure 1.
General characteristics of 8 eligible articles are outlined
in Figure 1. Data were composed of eight studies including
9 treatmentarms;222 subjects in the treatmentarmand239
subjects in control group. These studies were published
between 2001 to 2017; and were done in the European
countries [6, 18, 28, 29] as well as in Iran [19, 22, 23, 30].
The largest trial enrolled 88 subjects and the smallest had
a sample size of 33 subjects. Two trials were carried out
exclusively onmen [16] andwomen [19], while others were
done on both sexes. All qualified studies recruited obese
individuals except two studies which were conducted on
subjects with type 2 diabetes [18] and healthy athletes
[23]. The participants’ age ranged from 18 to 75 years. A sin-
gle study was performed on two separate populations with
two different doses of L-arginine, thus we considered it as
two studies [30]. L-arginine was used in various ranges of
between 2 g/day to 9 g/day among these studies. Supple-
mentation periods ranged from 3 up to 25 weeks.
Among studies that examined the impact of L-arginine
supplementation on body weight, 3 studies reported a
significant reduction [28, 30], while changes in bodyweight
were not significant in the other trials [18, 19, 22, 23]. With
regards to BMI, a significant reduction was achieved in 2
studies [30], however, the remaining studies failed to find
a significant effect [6, 22, 23, 28, 29]. In addition, half of
the included studies obtained a significant reduction in
WC after L-arginine administration than the control group
[28, 30] and in the other half of the studies, such significant
results were not observed (Table I).
Effect of L-arginine supplementation on
body weight
Pooled results from 6 studies with 7 treatment arms indi-
cated that body weight was not significantly reduced with
L-arginine supplementation as compared to placebo
(WMD:0.57 kg;95%CI:1.77 to0.61, P =0.34); with sig-
nificant between-study heterogeneity (I2 = 66.2 %, P =
0.007) (Figure 2). Subgroup analysis based on treatment
dosage (I2 = 0.0%, P = 0.84), duration (I2 = 2.1%, P =
0.38), and baseline BMI (I2 = 0.0%, P = 0.78) disappeared
the heterogeneity (Table II). Interestingly, a significant
reduction in body weight was reached in studies in which
L-arginine was consumed over or equal a period of 8weeks
(WMD:3.28 kg, 95%CI:5.55, 1.01, P = 0.005).
Effect of L-arginine supplementation on
body mass index
Combining findings from 7 treatment arms demonstrated
that L-arginine supplementation, as compared to placebo,
was not associated with a significant reduction in BMI
(WMD: 0.51 kg/m2; 95% CI: 1.11 to .08, P = 0.09)
(Figure 3), when the between-study heterogeneity was high
(I2 = 82.1%,P = <0.001). Subgroup analysis by the interven-
tion dosage (I2 = 0.0%, P = 0.86), follow-up duration (I2 =
59.8%, P = 0.11), and baseline BMI (I2 = 0.0%, P = 0.97 &
I2 = 0.0%, P = 0.61) disappeared the heterogeneity
(Figure 2). Although the majority of our subgroup analyses
did not change the findings, a significant reduction in
BMI was detected among studies which used < 8 g/day
L-arginine (WMD: 0.22 kg/m2, 95% CI: 0.42, 0.02,
P = 0.03) and those with a duration of  8 weeks (WMD:
0.71 kg/m2, 95%CI:1.12, 0.30, P = 0.001).
Effect of L-arginine supplementation on
waist circumference
Pooling effect sizes from 5 studies with 6 treatment arms,
L-arginine supplementation comparing to placebo
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significantly reduced waist circumference (WMD: 2.97
cm;95%CI:4.75 to1.18, P=0.001) (Figure4),witha sig-
nificant between-study heterogeneity (I2 = 82.2%,
P = < 0.001). Between-study heterogeneity was disap-
peared after subgroup analysis by baseline BMI (I2 =
0.0%, P = 0.56).
Total articles identified through database searching 
(n=1598)
303 duplicates excluded
Articles screening on the base of title/abstract
(n=1295)
Full-text articles assessed for eligibility (n=51)
1244 were excluded
7 Studies included in in the meta-analysis of L-arginine and body weight
7 Studies included in in the meta-analysis of L-arginine and BMI
6 Studies included in in the meta-analysis of L-arginine and waist circomferences
43 Full-text articles excluded
animal studies (n=9)
done on children (n=4)





Figure 1. Summary of the process of study selection
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To explore the influence of each single study on the overall
effect size, we excluded studies from the analysis, step by
step. We found no significant effect of any individual study
on the overall effect sizes of body weight, BMI and waist
circumference.
Publication bias
Visual inspectionof the funnelplots of standarderrorversus
effect size (WMD) for our three outcomes did not show any
evidenceof asymmetry (Figure5). These findingswere con-
firmedby theuseofEgger’s regression tests for bodyweight
(P = 0.27), BMI (P = 0.37), and WC (P = 0.54).
Discussion
In the present meta-analysis, we found a significant reduc-
tion in WC after L-arginine supplementation. However, L-
arginine supplementation had no significant effect on body
weight and BMI. Subgroup analyses indicated that body
composition indicesmight significantly reduce in trials last-
ing  8 weeks and used < 8 g/d L-arginine.
L-arginine supplementation tends to significantly lower
waist circumference by 2.97 cm, compared to placebo.
Several studies are available to support the anti-adiposity
effects of L-arginine. In line with the present study, a pilot
study by Ryan et al showed that receiving 3 g of L-arginine
three times aday for 12weeks, led to significant reduction in
waist circumference [20]. Also, several animal Studies
demonstrated that L-arginine supplementation reduces
fat mass and increases lean body mass [31–33]. In contrast,
Alizadeh et al in a clinical trial examined the effect of hypo-
caloric diet with or without L- arginine, the anthropometric
measures were not significantly different before and after
the intervention [19].
Thismeta-analysis didnot showasignificant reduction in
weight andBMIafterL-arginine supplementation. Inaccor-
dance with our findings, a randomized clinical trial by
Pahlavanietaldidnot showasignificanteffectofL-arginine
supplementation on body weight and BMI in male athletes
[23].Moreover, twoother trials have reached the same find-
ings [14, 18].Otherwise, thereareonly twostudies showeda
significant reduction in body weight and BMI after L-Argi-
nine supplementation [28, 30]. It should be noted that body
weight and bodymass index are not valid tools for measur-
ing fat mass tissue because they could not differentiate fat
and muscle and bone masses, while, waist circumference
is considered as a better indicator of body fat [34, 35].
The controversial findings from different studies in this
area can be partially explained by the different dosages
of L-arginine supplementation and duration of studies.
L-arginine dosage and study duration were as the potential
Figure 2. Forest plot of randomized controlled trials investigating the effects of L-arginine on body weight.
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sources of heterogeneity in our study. Moreover, 8weeks
supplementation with L-arginine and with a dose of < 8
g/day significantly reduced BMI and body weight and
BMI in our subgroup analysis, respectively. However, the
highest dosage in which one can be relatively assured that
no side effects will occur over a lifetime, has been recom-
mended at 20 g of L-arginine per day in supplemental form
[36].
L-arginine is a semi-essential amino acid consisted of 7%
of total amino acids in the usual humandiet [37]. L-arginine
improves endothelial function, insulin sensitivity, and
immunecell function.Furthermore, it isused inproteinsyn-
thesis [14, 15, 38]. L-arginine induces the expression of key
genes in adipose tissue which may subsequently increase
fatty acid and glucose oxidations [33]. These effects
might be due to increasing NO production and subsequent
up-regulation of AMP-activated protein kinase, NO syn-
thase-1, and peroxisome proliferators expression, and
activation of the receptor γ coactivator-1α and hemeoxyge-
nase-3 [32, 33, 39]. Increases in AMP-activated protein
kinase and peroxisome proliferator-activated receptor
gamma coactivator-1alpha concentrations will induce lipid
utilization, insulin signaling and glucose transport [40, 41].
Therefore, L-arginine may increase NO concentration
which has been associated with lower risk of abdominal
adiposity [42]. In addition, L-arginine might enhance lipo-
genesis in adipose tissue [43] by increasing the expression
of peroxisome proliferator-activated receptor (PPAR)
gamma, which stimulates differentiation and proliferation
of preadipocytes [44]. However, according to our subgroup
analysis,WCwassignificantly reducedonly ingrade 1obese
subjects, but not in individuals with grade 2 obesity.
Table II. Results of subgroup analysis of included randomized controlled trials in meta-analysis of L-arginine supplementation and obesity
indices
Group No. of comparisons Net change (95% CI) P significance P-heterogeneity I2 (%)
Body weight
L-arginine dose (g)
< 8 g 5 0.44 (1.06, 0.17) 0.15 0.004 73.9
 8 g 2 0.63 (0.59, 1.85) 0.31 0.84 0.0
Trial duration
< 8weeks 4 0.03 (0.60, 0.53) 0.91 0.38 2.1
 8 weeks 3 3.28 (5.55, 1.01) 0.005 0.02 72.4
Baseline BMI
Overweight (<30) 3 0.46 (1.23, 0.30) 0.23 0.78 0.0
Obesity grade 1 (30 < BMI < 35) 3 0.13 (0.68, 0.94) 0.75 0.001 86.6
Obesity grade 2 (35) 1 2.49 (6.50, 1.52 0.22 – –
BMI
L-arginine dose (g)
< 8 g 5 0.22 (0.42, 0.02) 0.030 <0.001 88.0
 8 g 2 0.01 (1.11,1.14) 0.979 0.863 0.0
Trial duration
< 8 weeks 2 0.06 (0.29,0.16) 0.576 0.115 59.8
 8 weeks 5 0.71 (1.12, 0.30) 0.001 <0.001 83.1
Baseline BMI
Overweight (<30) 2 0.19 (0.43, 0.05) 0.12 0.97 0.0
Obesity grade 1 (30 < BMI < 35) 2 0.24 (0.61, 0.12) 0.19 <0.001 96.9
Obesity grade 2 (35) 3 0.33 (1.21, 0.53) 0.44 0.61 0.0
WC
L-arginine dose (g)
< 8 g 3 3.33 (4.15, 2.50) <0.001 0.035 70.2
 8 g 3 3.74 (4.71, 2.77) <0.001 <0.001 90.4
Trial duration
< 8 weeks 2 3.86 (4.56, 3.16) <0.001 0.006 86.5
 8 weeks 4 2.02 (3.43, 0.61) 0.005 0.002 80.5
Baseline BMI
Obesity grade 1 (30 < BMI < 35) 3 4.03 (4.71, 3.35) <0.001 0.003 82.4
Obesity grade 2 (35) 3 0.50 (2.12, 1.11) 0.54 0.56 0.0
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To the best of our knowledge, this is the first systematic
review and meta-analysis which evaluated the effects of
L-arginine supplementation on obesity indices including
body weight, BMI, and waist circumference. Egger regres-
sion tests for the effect of L-arginine supplementation pro-
vided no evidence of substantial publication bias in this
meta-analysis. However, there were some limitations in
the current study including (i) high levels of heterogeneity
Figure 3. Forest plot of randomized controlled trials investigating the effects of L-arginine on Body mass index (BMI).
Figure 4. Forest plot of randomized controlled trials investigating the effects of L-arginine on waist circumference (WC).
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was observed in combined analysis, (ii) the type of study
population, dosage of L-arginine supplementation and
duration of trials were different, (iii) there were some stud-
ies that did not provide admissible data or lacked a placebo
group.
The present meta-analysis pooled results from RCTs in
regard to theeffectof theL-arginineadministrationonbody
weight, BMI, and waist circumference; Our findings indi-
cate that L-arginine supplementation might reduce waist
circumference. However, there was no significant effect
on body weight and BMI.
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